Stay updated on CARPALL: CAR T-cells for CD19+ Malignancies Clinical Trial
Sign up to get notified when there's something new on the CARPALL: CAR T-cells for CD19+ Malignancies Clinical Trial page.

Latest updates to the CARPALL: CAR T-cells for CD19+ Malignancies Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content or functionality of the page.SummaryDifference0.3%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference1.0%
- Check30 days agoChange DetectedThe page has updated its status from 'Active, not recruiting' to 'Recruiting' for the CARPALL study, indicating a significant change in the availability of participation in this clinical trial. Additionally, the study's focus has shifted from CD19+ hematological malignancies to specifically targeting CD19+ and CD22+ Acute Lymphoblastic Leukaemia.SummaryDifference4%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference6%
- Check95 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.3%
Stay in the know with updates to CARPALL: CAR T-cells for CD19+ Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CARPALL: CAR T-cells for CD19+ Malignancies Clinical Trial page.